Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

$6M from Sprott / Trading at Just 30% of the Sector Average EV/R Multiple

CLICK HERE TO READ THE FULL REPORT FULL DISCLOSURE: New Age Metals is a client of Stockhouse Publishing.
Fundamental Research | June 11, 2021 |

Analyst: Acquisition by Colorado-Based Specialty Pharma 'Could Bolster Revenue 400%'

The benefits and terms of the agreement are outlined in a Ladenburg Thalmann report. In a Sept. 18 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported that Aytu BioScience Inc. (AYTU:NASDAQ) signed a definitive agreement to acquire Innovus Pharmaceutic...
Streetwise Reports | September 25, 2019 |

Biopharma 'Keeps Executing and Securing Milestones'

The company's latest achievement and partnership potential are addressed in a ROTH Capital Partners report. In a Dec. 12 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Daré Bioscience Inc. (DARE:NASDAQ) received U.S. Food and Drug Adminis...
Streetwise Reports | December 19, 2019 |

Trump Impeached in the House! Is It Time for Gold Now?

Last week, the House voted to impeach Donald Trump. This is the third time in the U.S. history such an event has happened to the sitting President. What does it imply for the gold market? Trump’s Impeachment, Explained On Wednesday, the House of Represe...
Arkadiusz Sieron | December 27, 2019 |

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. In a Jan. 13 research note, Dawson James Securities analyst Jason Kolbert reported that Daré Bioscience Inc. (DARE:NASDAQ) partnered with Bayer, the company beh...
Streetwise Reports | January 16, 2020 |

High-Grade Values; Preliminary Exploration Across Multiple Properties

(Click the image to read the report.) Market research firm Fundamental Research Corp. recently initiate coverage into Falcon Gold Corp. ( TSX-V: FG ) labelling the Canadian mineral exploration company as a “buy”. Falcon Gold is build...
Fundamental Research | October 26, 2020 |

This Royalty Generator Expects to Cash In On Multiple Assets

https://soundcloud.com/proven-and-probable/david-cole https://www.streetwisereports.com/article/2020/01/16/royalty-firm-expects-to-cash-in-on-serbian-asset.html David Cole the CEO of EMX Royalty ( TSX.V: EMX | NYSE: EMX) , sits do...
Maurice Jackson | January 16, 2020 |

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. In a May 26 research note, ROTH Capital Partners analyst Tony Butler purported that Atara Biotherapeutics Inc.'s (ATRA:NASDAQ) "updated data from the Phase 1 ...
Streetwise Reports | May 28, 2020 |

Oil’s Ongoing Struggle at Multiple Resistances. Resolution Just Ahead?

Although crude oil futures moved a bit higher yesterday, the major resistance zone created by three gaps and the 61.8% Fibonacci retracement again stopped the buyers. A pullback followed, and the futures invalidated the earlier breakout above the previous peaks. Tog...
Nadia Simmons | December 9, 2019 |
1 2 3 4 5 6 7 8 9 10 ...